CSF3 and lymphoma: In summary, the significantly poorer outcome in lymphoma patients requiring Plerixafor in addition to G-CSF for a sufficient stem cell mobilization procedure regarding PFS, the slower engraftment kinetics and the greater transfusion requirements might suppose that these patients probably had a significantly higher and more stem cell-toxic pre-mobilization chemo-/radiotherapy burden and probably per se had more aggressive lymphoma subtypes.